Migraine Mode — On

Low-glare display activated. Optimized for light-sensitive viewing.

Clinical Standards & Case Frameworks

The Standards
We Hold Ourselves To

A complete reference for the clinical commitments, patient fit criteria, consultation dossier structure, institutional credentials, and dual-specialty case framework that define Monti Institute of Neuro Aesthetics — for patients who want to understand not just what we do, but how and why we do it.


The Standard We Hold Ourselves To

We do not offer commitments we do not intend to keep. The following statements represent the actual operating principles of this practice — the standards against which every clinical decision, every appointment, and every patient relationship at Monti Institute is measured.

01

We do not treat what we have not evaluated.

Every recommendation — neurological or aesthetic — follows a thorough, individualized clinical evaluation. Treatment is never offered before a clinical indication is established.

02

We recalibrate when the evidence requires it.

No patient remains on a regimen that is not producing meaningful results. Outcomes are tracked at every interval. Plans change when the clinical picture warrants — not when it is convenient.

03

We practice restraint as a clinical discipline.

In both neurological and aesthetic medicine, knowing when not to intervene is as consequential as knowing when to act. Conservative calibration is not a limitation of this practice — it is a defining feature of it.

04

We measure quality, not volume.

The practice is intentionally small. Appointment length is governed by clinical necessity, not scheduling efficiency. This is a deliberate institutional decision, not an operational aspiration.

05

We stay with you for the long term.

Neurological care and aesthetic medicine both require longitudinal physician relationships to produce lasting outcomes. The same physician is present at every visit — and carries the full context of your case.

06

We ground every decision in anatomical evidence.

In aesthetic medicine, we treat the face as an integrated anatomical structure — not a collection of features. In neurology, we treat migraine as a complex neurological disease — not a symptom to suppress.

This Practice Is Designed For

The patient who has been through the system Those who have managed chronic migraine or complex neurological symptoms across multiple practices and found that the 12-minute appointment and the standard protocol did not hold. You are ready for a physician who will review your full history — and build something different from it.

The patient who values continuity You want to build a relationship with a physician who knows your case — not reintroduce yourself at every visit. You understand that good neurological care is a sustained partnership, not a series of isolated encounters.

The aesthetic patient who insists on precision You are not seeking transformation. You are seeking refinement — conservative, anatomically guided, and undetectable. You want a physician-led experience, not a high-volume clinic, and you understand that the best aesthetic outcomes are built gradually over time.

The discerning patient who recognizes the difference You can identify the gap between adequate care and genuinely excellent care — and you are no longer willing to accept the former. You understand that clinical depth, physician continuity, and unhurried evaluation are worth seeking out.

The patient who is ready to commit Meaningful neurological and aesthetic outcomes are not produced in a single visit. You are ready for a long-term plan, built around your specific case — and designed to produce results that hold.

“The patients who come here are not looking for the nearest available appointment. They are looking for a physician who will actually think about their case.”

The Monti Institute Philosophy
Clinical Credentials & Institutional Affiliations
ABIM Board-Certified Internal Medicine
ACP American College of Physicians
NBPAS National Board of Physicians & Surgeons
FAACM® American Academy of Cosmetic Medicine
MCG Assoc. Prof. Medical College of Georgia
FDA FDA-Approved Clinical Protocols
ECFMG International Medical Graduate Certified
Following Your First Visit

The Consultation
Dossier

Issued at the conclusion of every initial consultation — not a visit summary. A clinical document.

At the close of your initial consultation, Monti Institute prepares a formal Consultation Dossier — a physician-authored clinical document that records, in precise anatomical and diagnostic language, everything established during your first appointment. It is not a visit summary, a patient portal extract, or a billing record. It is a structured clinical instrument: your diagnostic formulation, the physician’s interpretive assessment of your history and presenting condition, the specific clinical reasoning that underlies every recommendation, and the individualized therapeutic architecture designed for your case. Where applicable, it includes annotated anatomical references, baseline clinical photography, and a documented indication for each proposed intervention. It is written to accompany you through every subsequent appointment at this practice — and to be coherent and substantive to any specialist you may choose to consult outside of it.

The Dossier exists because we believe patients deserve to leave their first appointment understanding exactly what was found, what it means, and what the plan is — in language that reflects the clinical depth of the conversation, not a condensed version of it. It is, ultimately, the record of a physician who was paying genuine attention. For neurological patients, it includes ICHD-3 diagnostic classification, prior treatment response documentation, and the clinical rationale for each proposed intervention tier. For aesthetic patients, it includes a comprehensive facial anatomical assessment, SMAS integrity evaluation, fat compartment mapping, bony architecture notes, and the proposed 12-month horizon treatment plan — with each modality justified against the anatomical findings. For patients presenting across both divisions, the Dossier synthesizes both clinical domains into a unified longitudinal care document — the kind that ensures that no aspect of your wellbeing is treated in isolation from the rest.

01

Diagnostic Formulation

Confirmed diagnosis with classification criteria, clinical reasoning, and differential considerations where applicable.

02

Therapeutic Architecture

The individualized treatment plan — every modality selected, sequenced, and justified against clinical findings.

03

Anatomical Baseline Assessment

For aesthetic patients: documented facial anatomy with SMAS, fat compartment, and bony architecture assessment.

04

12-Month Horizon Plan

Staged treatment schedule with defined evaluation intervals and outcome benchmarks against which results are measured.

05

Prior Treatment Record

Documented history of prior interventions, responses, failures, and the clinical reasoning for departure.

06

Physician Clinical Commentary

A physician-authored interpretive note — the kind of clinical thinking that rarely survives the standard visit summary.

Dual-Specialty Case Case No. MI–001  ·  Combined Neurological & Aesthetic Medicine Patient identity anonymized. Published with informed consent. All clinical outcomes independently verified.

Concurrent Management of Chronic Migraine with Aura and
Structural Facial Aging in a Patient with Shared Neurovascular Etiology

A retrospective clinical case documenting the diagnostic, therapeutic, and outcomes framework for a patient presenting to Monti Institute with co-occurring high-frequency migraine with aura and multi-zone facial structural aging — managed concurrently across both clinical divisions under unified physician oversight.

Clinical Presentation & Diagnostic Context

The patient, a 48-year-old woman, presented with an 11-year history of high-frequency episodic migraine with visual aura, averaging 14 headache days per month over the preceding six months. Prior therapeutic trials included three oral preventive agents (topiramate, amitriptyline, propranolol), one CGRP receptor antagonist (discontinued secondary to adverse effect profile), and episodic triptans with diminishing efficacy. The patient reported a 60% reduction in functional capacity on headache days, significant sleep fragmentation, and withdrawal from professional responsibilities during migraine episodes.

Concurrently, the patient reported aesthetic concerns that had been deferred for several years during neurological treatment pursuit: bilateral midface descent with malar flattening, periorbital hollowing, deepening of the labiomental fold, and generalized skin quality deterioration. She expressed specific interest in physician-led, anatomically conservative intervention — and had declined treatment at two prior aesthetic clinics citing concerns about the volume of product proposed and the absence of formal clinical documentation.

Of clinical significance: the patient’s migraine aura pattern included visual scotomata, consistent with cortical spreading depression originating in the occipital cortex. The neurovascular relationship between her trigeminal sensitization and the periorbital anatomy relevant to her aesthetic concerns was noted during initial assessment as a factor requiring coordinated clinical consideration in treatment sequencing.

Neurological Therapeutic Architecture — Migraine Management

Following formal ICHD-3 classification confirming chronic migraine with aura, the neurological treatment plan was established in three tiers, sequenced to establish pharmacological stability before introducing interventional components.

Tier I CGRP monoclonal antibody (fremanezumab, quarterly dosing). Selected for its mechanism specificity, tolerability profile superior to prior oral agents, and evidence base in high-frequency episodic migraine with aura.
Tier II OnabotulinumtoxinA for chronic migraine (155u, 31-site PREEMPT paradigm). Introduced at Month 3 following CGRP stabilization, with specific attention to injection site depth in the periorbital and frontalis regions to avoid compromise of aesthetic treatment zones.
Tier III IV magnesium sulfate rescue protocol (monthly during high-frequency periods, tapered to as-needed following Month 6 stabilization).

Aesthetic Therapeutic Architecture — Full-Face Rebalancing

Aesthetic intervention was initiated at Month 4 following documentation of neurological stability under the CGRP and Botox combined regimen. The sequencing decision was clinically deliberate: OnabotulinumtoxinA injected for migraine would have already established a muscle response pattern in the frontalis and periorbital musculature, providing a defined neuromuscular baseline against which aesthetic neuromodulation could be precisely calibrated.

Full-face anatomical assessment documented: Grade II malar volume loss with infraorbital rim recession, moderate SMAS laxity producing early jowl formation, bilateral tear trough deformity secondary to SOOF compartment deflation, and temporal hollowing consistent with frontotemporal fat compartment atrophy. Bony resorption of the zygoma and pyriform aperture was identified as the primary structural contributor to midface descent and was addressed prior to any superficial soft-tissue correction.

Phase 1 Deep periosteal volumization at malar eminence and infraorbital rim with high-G′ calcium hydroxylapatite (Radiesse) to address bony resorption foundation.
Phase 2 Intermediate-layer SOOF and tear trough correction with low-viscosity hyaluronic acid (Belotero Balance) using retrograde linear threading technique.
Phase 3 Poly-L-lactic acid (Sculptra, 2 vials, bilateral temporal and cheek) for biostimulatory neocollagenesis in the dermal matrix, staged at 6-week intervals over three sessions.
Phase 4 Aesthetic neuromodulation (30u OnabotulinumtoxinA) precisely dosed to complement, not compound, the neurological Botox already established across 31 medical sites.

The Dual-Specialty Coordination Principle

This case illustrates the structural advantage of concurrent neurological and aesthetic management under unified physician oversight. The total OnabotulinumtoxinA dose administered across both divisions — 185 units — was carefully mapped so that the 31-site neurological protocol and the 8-site aesthetic protocol occupied complementary anatomical territories without redundancy or competition. A practitioner administering aesthetic Botox without awareness of the pre-existing neurological injection map would have no basis for this calibration.

Similarly, the deferral of aesthetic intervention until neurological stability was documented was not a conservative precaution — it was a clinical requirement. Introducing facial volumization into an actively unstable migraine pattern would have produced a confounded baseline against which aesthetic outcomes could not have been reliably evaluated. The sequencing was medicine, not scheduling preference.

Migraine Frequency

14 → 3

Headache days per month at presentation vs. Month 9 documented outcome.

Treatment Duration

12 Months

Complete dual-specialty treatment and 12-month horizon review period.

Total Botox — Both Divisions

185u

155u neurological (PREEMPT) + 30u aesthetic, mapped to non-competing anatomical territories.

Month 0 Initial consultation. Diagnostic formulation. Consultation Dossier issued.
Month 1 CGRP monoclonal antibody initiated.
Month 3 Neurological stability documented. Botox (155u) — PREEMPT protocol.
Month 4 Aesthetic Phase 1–2 initiated. Full-face rebalancing — deep and mid-layer.
Months 4–8 Sculptra biostimulation (3 sessions). Aesthetic neuromodulation at Month 6.
Month 12 12-month horizon review. Migraine: 3 days/month. Aesthetic outcomes photographically documented.
Ready to Begin

Schedule a Consultation

Every engagement begins with a comprehensive, unhurried clinical evaluation with Dr. Monti. Your Consultation Dossier is issued at the conclusion of your first visit — a formal record of everything established, everything planned, and the reasoning behind it.